Efficacy Outcomes

Of the 91 patients in this study during treatment with lepirudin, four (4.4%) experienced new thromboses, three (3.3%) underwent limb amputation, and 13 (14.3%) deaths occurred. Most of the deaths were related to underlying disease, not to HIT or treatment with lepirudin. Since patients were counted only once if multiple events occurred, the incidence of the composite endpoint was 18/91 (19.8%) (Table 5). The median platelet count rebounded to 150 X 109/L within 4 days of beginning lepirudin treatment.

0 0

Post a comment